期刊文献+

多发性骨髓瘤伴髓外病变研究进展 被引量:2

Progress in extramedullary disease in multiple myeloma
原文传递
导出
摘要 多发性骨髓瘤(MM)是一种以分泌单克隆免疫球蛋白或其片段(M蛋白)为特征的恶性浆细胞疾病。一般情况下,骨髓瘤细胞局限于髓内,但在初诊或疾病进展过程中均可出现髓外病变(EM),伴EM的MM患者预后较差。根据EM的发生方式可将其分为单纯骨相关髓外病变(EM-b)和软组织相关髓外病变(EM—s)。EM—b为骨髓瘤细胞突破骨皮质累及周围连续性软组织的病变;EM-s为通过血源播散到髓外的软组织或其他器官的病变。研究发现不论是初诊MM还是疾病进展过程中发生的EM-s,其预后都比EM-b差。因此,文章主要综述EM-b和EM-S的区别,包括两者的发病率、生物学特征、临床表现、治疗及预后。
出处 《肿瘤研究与临床》 CAS 2016年第11期785-789,共5页 Cancer Research and Clinic
基金 国家自然科学基金(81172247) 陕西省社会发展科技攻关项目(2016SF.071)
  • 相关文献

参考文献2

二级参考文献18

  • 1Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma[J]. Ann Hematol, 2015, 94(3):445-452.
  • 2Wirk B, Wingard JR, Moreb JS. Extramedullary disease in plasma cell myeloma: the iceberg phenomenon[J]. Bone Marrow Transplant, 2013, 48(1): 10-18.
  • 3Shin HJ, Kim K, Lee JW, et al. Comparison of outcomes after autologous stem cell transplantation between myeloma patients with skeletal and soft tissue plasmacytoma[J]. Eur J Haematol, 2014, 93(5): 414-421.
  • 4Ludwig H, Miguel JS, Dimopoulos MA, et al. International Myeloma Working Group recommendations for global myeloma care[J]. Leukemia, 2014, 28(5): 981-992.
  • 5Bladé J, Fernández de Larrea C, Rosi?ol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach[J]. J Clin Oncol, 2011, 29(28): 3805-3812.
  • 6Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma[J]. Leukemia, 2011, 25(6): 906-908.
  • 7Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse[J]. Haematologica, 2014, 99(2): 360-364.
  • 8Chen HF, Wu TQ, Li ZY, et al. Extramedullary plasmacytoma in the presence of multiple myeloma: clinical correlates and prognostic relevance[J]. Onco Targets Ther, 2012, 5: 329-334.
  • 9Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents [J]. Haematologica, 2012, 97(11): 1761-1767.
  • 10Papanikolaou X, Repousis P, Tzenou T, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting with extramedullary relapse [J]. Leuk Lymphoma, 2013, 54(7):1459-1464.

共引文献12

同被引文献10

引证文献2

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部